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with few studies: Empirical and simulation studies
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Abstract
Background: Standard random-effects meta-analysis methods perform poorly when applied to few studies
only. Such settings however are commonly encountered in practice. It is unclear, whether or to what extent
small-sample-size behaviour can be improved by more sophisticated modeling.
Methods: We consider likelihood-based methods, the DerSimonian-Laird approach, Empirical Bayes, several
adjustment methods and a fully Bayesian approach. Confidence intervals are based on a normal approximation,
or on adjustments based on the Student-t-distribution. In addition, a linear mixed model and two generalized
linear mixed models (GLMMs) assuming binomial or Poisson distributed numbers of events per study arm are
considered for pairwise binary meta-analyses. We extract an empirical data set of 40 meta-analyses from recent
reviews published by the German Institute for Quality and Efficiency in Health Care (IQWiG). Methods are
then compared empirically and as well as in a simulation study, based on few studies, imbalanced study sizes,
and considering odds-ratio (OR) and risk ratio (RR) effect sizes. Coverage probabilities and interval widths for
the combined effect estimate are evaluated to compare the different approaches.
Results: Empirically, a majority of the identified meta-analyses include only 2 studies. Variation of methods or
effect measures affects the estimation results. In the simulation study, coverage probability is, in the presence
of heterogeneity and few studies, mostly below the nominal level for all frequentist methods based on normal
approximation, in particular when sizes in meta-analyses are not balanced, but improve when confidence
intervals are adjusted. Bayesian methods result in better coverage than the frequentist methods with normal
approximation in all scenarios, except for some cases of very large heterogeneity where the coverage is slightly
lower. Credible intervals are empirically and in the simulation study wider than unadjusted confidence intervals,
but considerably narrower than adjusted ones, with some exceptions when considering RRs and small numbers
of patients per trial-arm. Confidence intervals based on the GLMMs are, in general, slightly narrower than those
from other frequentist methods. Some methods turned out impractical due to frequent numerical problems.
Conclusions: In the presence of between-study heterogeneity, especially with unbalanced study sizes, caution is
needed in applying meta-analytical methods to few studies, as either coverage probabilities might be
compromised, or intervals are inconclusively wide. Bayesian estimation with a sensibly chosen prior for
between-trial heterogeneity may offer a promising compromise.
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Background
Meta-analyses of few studies are common in practice. For instance, a review of the Cochrane Library
revealed that half of the meta-analyses reported in the Cochrane Library are conducted with two
or three studies [1]. However, standard random-effects meta-analysis methods perform poorly when
applied to few studies only [2, 3]. It is unclear, whether or to what extent small-sample-size be-
haviour can be improved by more sophisticated modeling. Bayesian random-effects meta-analyses
with weakly informative priors for the between-study heterogeneity have been proposed for this
setting [4] and their performance has been found to be satisfactory in numerical applications and
simulations [3, 5]. Other alternative approaches including likelihood based methods have been men-
tioned as potential remedies [6].
In meta-analyses commonly a two-stage approach is applied. In the first step, data from the
individual studies are analyzed resulting in effect estimates with standard errors. These are then
combined in a second step. As individual patient data (IPD) are not generally available and effects
with standard errors can typically extracted from publications, this two-stage approach makes a
lot of sense from a practical point of view. With binary data, however, the individual patient data
are summarized by 2×2 frequency tables and are usually readily available from publications [7].
Therefore, preference might be given to one-stage approaches in this setting over the commonly
applied two-stage approach. However, numerical differences between the one-stage and two-stage
approaches have been found to be small in a simple Gaussian model [8]. If differences are observed,
these arise mostly for differing models [9, 10] or relate not to the main effects but interactions
[11]. So, while a simpler two-stage model is often sufficient (especially in case of many studies and
non-rare events), a one-stage model may on the other hand be expected to be more flexible and
more exact [12]. A Bayesian approach may be more suitable especially in cases of few studies [3–5].
For a more detailed discussion of common models for binary data, see also Jackson et al. [13].
Although some model and method comparison studies appeared recently [13, 14], a systematic
evaluation and comparison of the various methods is lacking in the context of few studies. Here we
intend to close this gap by an empirical study and comprehensive simulations.
This manuscript is structured as follows. In the following section we summarize the meta-analysis
approaches compared, the extraction of the empirical data set and the setup of the simulation study.
Then the results of the empirical study as well as of the simulation study are presented. We close
with a brief discussion and some conclusions.
Methods
Modeling approaches
In the following, we will consider meta-analyses based on binary endpoints, where each study’s
outcome may be summarized in a 2×2 table giving the the numbers of participants with and
without an event in both study arms.
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Normal-normal hierarchical model (NNHM)
Model specification
Traditionally, meta-analytical methods often follow a contrast-based summary measure approach
which is based on the log-transformed empirical estimates of the outcome measure and their stan-
dard errors, and assuming an approximate normal likelihood [15].
In a common situation in random-effects meta-analysis, k independent studies are available in
which the treatment effect θi is the parameter of interest (i = 1, 2, . . . , k). From each study, an
effect estimate θˆi with its estimated variance (squared standard error) σ
2
i
is provided for this
treatment effect. It is then assumed that θˆi follows a normal distribution centered around the
unknown true treatment effect θi, with the variance σ
2
i
accounting for the measurement uncertainty,
or within-study variation. Although σ2
i
usually only is an estimate, it is commonly treated as known.
The θi may vary across study populations around a global mean µ due to the between-study
heterogeneity τ . After integrating out the parameters θi, the marginal model can be expressed as
θˆi ∼ N (µ, σ
2
i + τ
2). (1)
This model is commonly applied to both log-transformed risk ratio (RR) or odds ratio (OR) mea-
sures of treatment effect for binary data θˆi [16, 17]; it is denoted as “model 1” in the investigation
by Jackson et al. [13].
Inference
We will consider frequentist and Bayesian approaches to inference within the generic NNHM. In the
frequentist approaches, an estimate of the between-study heterogeneity τ is usually required first.
Different estimators are available; in the following we consider the commonly used DerSimonian-
Laird (DL) [18], maximum likelihood (ML), restricted maximum likelihood (REML) [19, 20] and
empirical Bayes (EB) estimators, the latter also being known as the Paule-Mandel estimator [21,
22]. Based on an estimate of this heterogeneity τˆ , the mean effect estimates are determined in a
subsequent step by conditioning on the τˆ value as if it were known.
The fully Bayesian estimation within the NNHM framework is done using three different prior
specifications for the between-study heterogeneity (τ). Uncertainty in the heterogeneity is naturally
accounted for when estimating the combined treatment effect µ by marginalisation. Especially if the
number of studies is small, however, the choice of priors matters, as has been discussed by Turner
et al. [23], Dias et al. [24, Sec. 6.2], or Ro¨ver [25]. We follow Friede et al. [3] and Spiegelhalter et
al. [26, Sec. 5.7] and consider two half-normal priors with scales 0.5 and 1.0 for the between-study
heterogeneity. These specifications include up to “fairly high” and “fairly extreme” heterogeneity
[26, Sec. 5.7.3], and they also span the range of values considered in the simulations (see Table 4).
In all of these approaches risk ratios (RR) and odds ratios (OR) can be used as the treatment effect.
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Generalized linear mixed models (GLMM)
Models
The statistical model may also be based directly on the count data, using either a binomial or
a Poisson assumption on the numbers of events per study arm. Generalized linear mixed models
(GLMMs) may then be fitted to the data, using a logarithmic link for Poisson rates or a logit link
for proportions. Treatment effects may be modeled based on ORs or RRs, and random effects may
be included at several stages in order to account for heterogeneity. In addition, we also consider
some approximate variants of these models. The models used are outlined briefly below; most of
these are also discussed in more detail by Jackson et al. [13].
Model specification and inference
If a Poisson distribution is assumed for the number of events per arm and study, a log-link will be
used to model the RR. Following Bo¨hning et al. [7, Ch. 2] this model is estimated using the profile
likelihood; in the following, this model will be denoted as the “PN-PL” model.
For binomially distributed numbers of events per study arm, a logit-link will be applied to model
ORs in a logistic regression. Four different specifications are included in the comparison. Uncon-
ditional logistic regression with fixed and random study-specific nuisance parameters as discussed
by Turner et al. [27] are considered (“UM.FS” and “UM.RS”, respectively, in the following). These
correspond to models 4 and 5 in Jackson et al. [13].
In addition, we follow van Houwelingen et al. [28] in using a conditional logistic approach, where
the total number of events per study is conditioned upon, in order to avoid the need to also model
their variability [19]. The likelihood of this conditional model can be described using Fisher’s non-
central hypergeometric distribution [28] (“CM.EL” in the following, and corresponding to model 7
in [13]).
Fisher’s non-central hypergeometric distribution may be approximated by a binomial distribution,
if the number of cases is small compared to the overall participants in that study [29]; this model
specification will be denoted by “CM.AL” in the following (approximate version of model 7 in [13,
Sec. 3.7.2]). All of the logistic regression models are fitted using maximum likelihood.
Confidence and credible intervals combined effects
The 95% credible intervals in the Bayesian estimation and confidence intervals in the frequentist
approaches are estimated for the combined treatment effect µ. The narrowest 95% highest pos-
terior density intervals are used in the Bayesian estimation. For the construction of confidence
intervals, Wald-type intervals based on normal quantiles are considered, which are known to be
anti-conservative when the number of studies is small or non-negligible amounts of heterogene-
ity are present [2, 3, 30, 31]. To account for this behaviour, confidence intervals are in addition
constructed using Student’s t-distribution in case of the GLMMs, and the Hartung-Knapp-Sidik-
Jonkman (HKSJ) adjustment [30–32] in case of the NNHM. The HKSJ-adjusted intervals tend to
be wider than the Wald-type intervals, although this is not strictly the case [2, 32, 33]. Knapp and
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Hartung [33] proposed a modification of the Hartung-Knapp-Sidik-Jonkman adjustment (mHKSJ)
correcting HKSJ-adjusted intervals in the cases where they are counterintuitively narrow. These
modified confidence intervals are also considered.
I2 as measure of between-study heterogeneity
The “relative amount of between-study heterogeneity” can be expressed in terms of the measure I2,
which expresses the the between-study variance (τ2) in relation to the overall variance (σ˜2) [34],
which is stated as
I2 =
τˆ2
σ˜2 + τˆ2
. (2)
In the calculation of I2, a “typical” σ˜2 value is required as an estimate of the within-study variances
σ2
i
. Higgins and Thompson [34] suggest a weighted average of the individual within-study variances
as “typical” value. This, together with the fact that the I2 is bounded between zero and one,
permits the interpretation of heterogeneity magnitude as a relative percentage. The I2 is used to
set the amount of heterogeneity in the simulation study. Hoaglin [35] remarks that the probability
for observing a moderate (estimated) I2 even in the absence of heterogeneity is dependent on the
number of studies included and is not negligible. As the I2 expresses the between-study variation
relative to the total variation, the same values of τ may lead to different values of I2, depending
on the precision of the underlying studies and should therefore always be interpreted as a relative
measure [36].
Extraction of the empirical data set
A data set of 40 meta-analyses was extracted from publications of the German Institute for Quality
and Efficiency in Health Care (IQWiG). IQWiG publications were searched chronologically for meta-
analyses of binary data in April 2017 starting with the most recent available ones and reaching back
to March 2012. In total, 521 documents were screened, including all document types in the search.
If a detailed and a short version of a document existed, only the detailed version was considered.
From documents including at least one meta-analysis of binary data, the first one was extracted to
obtain a realistic data set with respect to the number of studies typically included in a meta-analysis
and the sample sizes of those studies. Meta-analyses involving studies with zero events in one or
more arms were excluded from the data set for better comparability of the evaluated methods.
Simulation procedure
To compare properties of the investigated approaches to meta-analysis, we conducted a Monte-Carlo
simulation adapting the setup from IntHout et al. [14] who described the simulation of 2×2 tables.
In deviation from IntHout et al. [14], series of trials with up to 10 studies were simulated, and each
series was repeated only 2000 times. Three different designs were considered, where in the first one
all studies were of equal size, one study was ten times larger than the other studies in the second,
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and one study was only a tenth of the size of the other studies in the third design. It should be
noted however that this ratio corresponds to extreme, but not unrealistic cases, as is also illustrated
in the right panel of Figure 1. The (less common) case of equal sizes is of interest here, as this is
where we expect the HKSJ methods to perform best [2, 14].
To generate dichotomous outcomes, p0 and I
2 have to be set in advance. Considered values of
the I2 correspond to levels of no, low, moderate, high and very high heterogeneity, respectively
[37]. Note however, that the same I2 value may correspond to different values of between-study
heterogeneity τ depending on the effect measure used, and on whether or not study sizes are
balanced; the resulting τ values are shown in Table 4. From the τ values one can see that in some
of the scenarios, the I2 settings imply unrealistically large absolute heterogeneity [26, Sec. 5.7.3],
which needs to be considered in the interpretation. This would be true for instance for odds ratios
with I2 in the range of 0.75 and 0.90 and one small study when τ is roughly in the range of 1
to 2 (see Table 4). The baseline event rate (p0) needs to be set as an additional parameter and
varies from 0.1 to 0.9 in steps of 0.2. The treatment effect θi is set to unity for both RR and OR,
which corresponds to the absence of an effect. Note that while for meta-analyses of continuous (or,
more specifically, normally distributed) endpoints the magnitude of the simulated treatment effect
(θi) should not affect performance, e.g. for binomial counts it may make a difference, as it affects
the chances of observing few or zero events in the treatment arm. However, since we chose not to
focus on rare-event issues, and in order to keep the number of simulation scenarios manageable,
only the case of no effect was investigated. For every combination of the simulation parameters
2000 repetitions are simulated. In case zero event counts occurred, for the models based on the
NNHM, a continuity correction of 0.5 was added to all cells of the affected study’s contingency
table. Zero counts, however, were rare in the scenarios considered. The simulation scenarios are also
summarized in Table 3. For more details on the simulation procedure see also IntHout et al. [14]
and Table 5 below. As in the case of the empirical data set, the two-sided significance level α was
set to 0.05. Different methods and scenarios are compared based on observed confidence or credible
interval coverage probabilities and lengths.
Estimation in R
The software environment R [38] and two of its extensions, the metafor [39, 40] and bayesmeta
[25, 41] packages are used with their default options. As no implementation in R was found for the
PL estimation of Poisson-normal model we translated the steps described by Bo¨hning et al. [7, Ch.
2] into R code which is shown in the appendix.
Results
Empirical Study
Most (419; 80%) of the 521 documents searched did not include a meta-analysis, because either the
assignment was canceled (11; 2%), the assignment had just started without results being available at
the time of search (70; 13%), no meta-analysis was included or accepted by the IQWiG (186; 36%),
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no study (34; 7%) or just one study (118; 23%) was identified. Out of the remaining 102 documents
which included at least one meta-analysis, 25 (5%) did not include any binary meta-analysis, 19
(4%) were network meta-analyses, and in 18 (3%) cases the first binary meta-analysis included at
least one study with zero events. An overview over the identified meta-analyses is given in Table 1;
the data are also available online [42].
In the original publications, a slight majority of studies (26 of 40) was analyzed using RR as the
effect measure. In the extracted data set, 21 out of the 40 meta-analyses (53%) included only 2 stud-
ies, while 10 (25%) consisted of three studies. Even in this small example, a common occurrence
of 2- and 3-study meta-analyses is found, which is also observed empirically by [43] and [44]. The
distribution of study sizes and endpoints is also illustrated on the left panel in Figure 1. With only
two studies included, three methods coincide: the DL, the REML and the EB estimation [45]. As
this is the case for a major share of the data set, these three methods are expected to show similar
results in the analysis. The maximum number of studies observed is 18. The original analyses were
based on the NNHM, and, with only the exceptions of the publications A15-45, S11-01 and A11-30
performed using DL variance estimation.
Imbalance in study sizes may influence the estimation of an overall treatment effect [2, 14, 46].
As IntHout et al. [14] observe in an empirical study, such unequal study sizes are common in meta-
analyses. In the data set extracted from IQWiG publications, ratios of sample sizes between the
largest and the smallest study in a meta-analysis ranged from 1.0 up to 15.8, with a mean of 3.4 and
a median of 1.9. Nearly half of the meta-analyses included at least one study twice as large as the
smallest study. In the NNHM, study-specific variances σ2
i
should roughly be inversely proportional
to sample sizes; imbalances in sample size then affect analysis via an imbalance in the σi. Ratios of
largest to smallest study sizes and variances using both effect measures for all studies are shown on
the right panel in Figure 1, where the ratio between the largest and the smallest value is ordered
by the ratio of sample sizes in descending order. It can be observed that the ratios of the variances
of ORs seem to vary more when study sizes are unbalanced than those of the RRs. However, they
both roughly follow the same pattern as the ratio of study sizes.
The extracted data set is then analyzed based on the models and methods described above. As
2×2 tables are available for all studies, both effect measures are used to summarize the individual
meta-analyses and to evaluate the influence of the choice of effect measure on the estimation re-
sults. The ratios of point estimates of the different methods against the standard DL approach are
illustrated by the first row of Figure 2 where the RR is displayed in the left and the OR in the right
panel. As expected, DL, REML and EB estimation coincide in the majority of cases including only
two studies [45]. These three estimators are also observed to behave comparable when more than
two studies are included, as do the point estimates of the Bayesian approach. The greatest deviation
from the standard DL approach is observed in the GLMMs in both effect measures. In the case
of OR as an effect measure, UM.FS and UM.RS perform comparable. CM.EL estimation does not
converge in all cases, however, in the cases where convergence was achieved, it is in line with DL
estimation. The CM.AL however, is in general different from the DL estimation. The Poisson-based
results also differ considerably from the DL estimates.
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The length of confidence intervals for the frequentist and credible intervals in the Bayesian esti-
mation are also of importance as it might not be possible to detect significant treatment effects if
intervals are inconclusively wide. For both effect measures, all intervals and the discussed adjust-
ments are shown in the second row in Figure 2. Again, the RR is displayed in the left and the OR in
the right panel. The Bayesian credible intervals are generally wider than the unadjusted confidence
intervals and more similar to the adjusted ones with respect to the median length, but exhibiting
less variability.
Simulation Study
Figures 3 and 4 illustrate the coverage rates (first row) and lengths (second row) of the 95%
confidence or credible intervals of the different methods for the relative risks and odds ratios,
respectively. All results shown here exemplarily refer to the combination of 100 participants per
arm and study and a baseline event rate of 0.7. Results of the other scenarios may be found in the
supplement. The different methods are indicated by colours, while the different adjustments are
indicated by the line type.
Non-convergence rates averaged over all scenarios and both effect measures are mostly negligi-
ble in the methods based on the normal likelihood on the log-scale (ML: 0.049%, EB: 0.032%,
HN(1.0): 0.002%, HN(0.5): 0.036%). Estimation based on REML or the methods taking the distri-
butional assumptions on the trial-arms lead to slightly higher non-convergence rates (REML: 0.43%,
UM.FS: 0.43%, UM.RS: 0.22%, CM.AL: 0.47%). The only method with high non-convergence rates
is CM.EL, with an average of 18%. None of the methods fully dominates the others over the range
of the investigated scenarios. Estimation using CM.EL for the binomial-normal model however was
computationally expensive and convergence was problematic in a large proportion of scenarios (us-
ing the default values), as has been noted before [13, 19]; these results are omitted here. Coverage
rates of all methods are comparable when either the number of studies included in each meta-
analysis is sufficiently large or when the heterogeneity is absent or low (I2≤0.25). However, given
the frequency with which 2- or 3-study meta-analyses occur empirically in our example data set
and others [43, 44] and the difficulties in the determination of the absence of heterogeneity [2] this
is hardly relevant in practice. In general when study sizes were not balanced, coverage rates for all
methods were substantially lower even in the presence of only low heterogeneity in the simulation
of OR, while Bayesian estimation and the adjustment of frequentist confidence intervals resulted in
better coverage when RR was used. This might be due to the I2 values translating to lower values
of absolute heterogeneity in the latter case. In the presence of heterogeneity, coverage could drop
as low as 40% for some extreme scenarios in both, frequentist and Bayesian estimation, resulting
in high false-positive rates. In general, it was also observed that one large study tended to lead to
lower coverage than one small study per meta-analysis in the frequentist methods when more than
k=2 studies are present, which is in line with [14]. This effect is more noticeable in the unadjusted
methods, in scenarios where the number of patients per arm (ni) is small, or when heterogeneity
(I2) is large. When considering k = 2 trials per meta-analysis, coverages are comparable (OR) or
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the effect is even reversed (RR). The frequentist methods based on the normal-normal hierarchical
model perform similarly, or, in the case of two studies per meta-analysis, even identically [45]. In
the case of heterogeneous data, in particular regarding small study sizes, all frequentist methods
perform below the nominal coverage probability when confidence intervals are not adjusted. In the
scenarios with unbalanced study sizes this is even more pronounced than in the balanced scenarios;
this is in line with the findings of [14] and [2]. Coverage can, at the cost of interval width, be
increased by either using the HKSJ or the mHKSJ adjustment, but the HKSJ adjustment yields in
some scenarios coverage probabilities which are still below the nominal level [14].
The length of confidence and credible intervals is illustrated in the second row of Figures 3 and 4.
Bayesian credible intervals are, as in the case for the empirical data set, in general wider than the
unadjusted confidence intervals from the frequentist estimations. When compared to adjusted con-
fidence intervals, Bayesian credible intervals tend to be, especially in the presence of heterogeneity
and with only two studies per meta-analysis, narrower than the frequentist intervals based on the
normal-normal model as long as the number of patients per trial arm is small. However, when ni
increases, this is no longer true for RR (in contrast to the scenarios using OR). These differences
may be due to the fact that idential I2 settings can imply very different (and sometimes possi-
bly unrealistically large) magnitudes of heterogeneity values on the τ scale, as can also be seen in
Table 4. In these extreme scenarios, adjusted frequentist confidence intervals are observed to be
inconclusively wide, with the exception of BN-UM.FS and BN-UM.RS, and especially when esti-
mation is based on the NNHM. In the other scenarios, Bayesian credible and adjusted confidence
intervals are comparable.
Discussion
In our empirical study we found that the majority of the 40 meta-analyses extracted from pub-
lications of IQWiG included only two studies. This is in agreement with a much larger empirical
investigation based on the Cochrane Library by Turner et al. [1]. This finding emphasizes the
need for methods appropriate for meta-analysis with few studies. Furthermore, varying methods
and / or effect measures lead to differences in the results for the 40 meta-analyses considered. This
demonstrates that prespecification of methods as well as effect measures is important for controlling
operating characteristics. The problems encountered in meta-analyses of few studies may mostly
be attributed to the estimation of heterogeneity, and in particular to the proper accounting for its
uncertainty in constructing intervals for the combined effect. The difference in performance between
different heterogeneity estimators is relatively small compared to the difference in whether or how
heterogeneity uncertainty is propagated through to the effect estimate [3].
In the simulation study, coverage probability was below the nominal level for all frequentist meth-
ods in the presence of heterogeneity and few studies. This phenomenon is even more pronounced
when studies included in a meta-analysis are of unequal size. However, coverage probabilities gener-
ally improve when confidence intervals are adjusted based on the Student-t-distribution. Bayesian
methods mostly result in better coverage across all scenarios, except for some cases of very large
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heterogeneity (in terms of τ) where the coverage is slightly lower. Credible intervals are empirically
and in the simulation study wider than unadjusted confidence intervals, but considerably narrower
than adjusted ones, with some exceptions when considering RRs and large numbers of patients per
trial-arm. Previous simulation studies comparing a more restricted set of methods including stan-
dard frequentist and Bayesian approaches only led to similar conclusions. The simulations presented
here considering a wider set of methods show that the issues entailed by the increased complexity
of some likelihood-based approaches may often outweigh their expected advantages [6]. However,
confidence intervals based on the GLMMs for example are in general slightly narrower than those
from other frequentist methods. Furthermore, certain maximum-likelihood methods turned out to
suffer from frequent numerical problems in the setting with few studies. To our knowledge, this has
not been described previously.
Our empirical investigation did not consider all IQWiG reports, but only the most recent 40 meta-
analyses at the time of extraction. A consideration of all meta-analyses might have led to a more
complete picture, but was not feasible with the resources of this project as no specific funding was
available. Furthermore, the simulation study could have been enriched by additional methods. For
instance, we only considered Bayesian two-stage approaches but did not include Bayesian approaches
utilizing the full information of the 2×2 tables. The latter was considered recently by [47] in the
context of network meta-analyses, where pairwise meta-analysis would be a special case. As for
the likelihood methods, we would expect that the results of the one-stage approach are overall
quite similar to those of the two-stage approach considered, maybe with the potential of some
small improvements. As discussed in the context of the simulation setup, a pre-specified I2 value
may correspond to rather different τ values, depending on the circumstances (see also Table 4).
Consequently, one may generally expect larger I2 values for log-RR endpoints, and smaller I2 values
for log-OR endpoints, while heterogeneity priors are probably best discussed at the scale of τ values
(a prior specification in terms of I2 would be possible [25], but this would be hard to motivate).
By relating the heterogeneity to the τ value, the question to consider is by what factor the true
RRs or ORs θi are expected to differ solely due to between-trial heterogeneity [26, Sec. 5.7.3], and
the reasonably expected range should then be covered by the prior. For example, a heterogeneity of
τ=1.0 implies that the central 95% of true study means (θi) span a range of a factor of 50 [3, 26]. The
HN(0.5)-prior confines τ to values below 1.0 with roughly 95% probability, while the HN(1.0)-prior
constitutes a conservative variation that instead allows for twice as large heterogeneity, implying a
plausible range of roughly up to factor of 502 = 2500.
The limits of applicability of approximate meta-analysis methods have been discussed from the
perspective of the NNHM by Jackson and White [48]. In the limit of many studies (large k) and
large sample sizes (large ni), the normal approximation usually works well. It starts breaking down,
however, when the number of studies (k) gets too small. The problem then is related to the esti-
mation of heterogeneity (τ) and proper accounting for the associated uncertainty; inference would
still be exact if the heterogeneity was known. In the frequentist context, use of the HKSJ adjust-
ment helps, especially if the study-specific standard errors are roughly balanced [49]. This is not so
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much of a problem when Bayesian methods along with reasonable priors are used; these methods
yield valid inference irrespective of the number of included studies [50]. Problems also arise when
events are rare or sample sizes (ni) are small. In either case, the chances of observing few or no
events in a treatment group increase, and normal approximations to the likelihood break down. In
such situations, a solution might be to resort to exact likelihoods respecting the discrete nature of
the data, for example a GLMM, which may again be done in frequentist or Bayesian frameworks
[7, 40, 51].
Conclusions
In the presence of between-study heterogeneity, especially with unbalanced study sizes, caution is
needed in applying meta-analytical methods to few studies, as either coverage probabilities of inter-
vals may be compromised, or they may be inconclusively wide. Bayesian estimation with sensibly
chosen prior for the between-study heterogeneity may offer a compromise and promising alternative.
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Figure 1 Characteristics of the data set extracted from IQWiG publications. Left side: Proportions of number of
studies included per meta-analysis out of n = 40. Colours indicate the effect measure used in the original
publications. Right side: Empirical distribution function for the proportion of study sizes (largest vs. smallest per
meta-analysis, black) and the proportion of study-specific variances (largest vs. smallest per meta-analysis) for the
log-transformed RR (green) and the log-transformed OR (orange). All meta-analyses are included for both effect
measures.
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Figure 2 Estimates of the combined treatment effect and lengths of confidence or credible intervals for both
effect measures, empirical data set. The first row shows the treatment effect estimates for the RR (left column) and
the OR (right column) compared to the standard DL approach. Colours indicate the various methods. The second
row illustrates the length of confidence or credible intervals and the respective adjustments, again for the RR (left
column) and the OR (right column).
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Figure 3 Coverage probabilities and lengths of 95% confidence or credible intervals for the overall effect for
RR effects based on the simulated data. The top panel shows the coverage probabilities of treatment effect CIs for
the different methods (colours) and adjustments (line types). The grey area indicates the range expected with 95%
probability if the coverage is accurate. The bottom panel similarly shows the lengths of 95% confidence or credible
intervals. Results are illustrated for a study size of ni=100 and a baseline event probability p0=0.7, and are based
on 2000 replications per scenario. CM.EL is omitted due to low convergence rates.
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Figure 4 Coverage probabilities and lengths of 95% confidence or credible intervals for the overall effect for
OR effects based on the simulated data. The top panel shows the coverage probabilities of treatment effect CIs for
the different methods (colours) and adjustments (line types). The grey area indicates the range expected with 95%
probability if the coverage is accurate. The bottom panel similarly shows the lengths of 95% confidence or credible
intervals. Results are illustrated for a study size of ni=100 and a baseline event probability p0=0.7, and are based
on 2000 replications per scenario. CM.EL is omitted due to low convergence rates.
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Tables
Table 1 Data extracted from IQWiG publications [42].
Number of Effect
No. Identifier Date Endpoint Page studies (k) measure
1 N15-06 2017-03 morning pain 85 5 OR
2 N15-11 2017-03 ear infection 62 2 OR
3 S15-02 2017-01 mortality 53 2 OR
4 D15-02 2017-01 mortality 74 2 OR
5 A16-71 2016-12 morbidity 5 6 OR
6 A16-38 2016-12 vomiting 4 2 RR
7 P14-03 2016-11 breast cancer screening 55 3 RR
8 N14-02 2016-08 remission from anxiety disorder 127 2 OR
9 A16-30 2016-08 AIDS-defining events 103 2 RR
10 N15-07 2016-08 ejaculation dysfunction 89 4 OR
11 A16-11 2016-06 serious adverse events 86 2 RR
12 A10-03 2016-04 serious adverse events 89 2 OR
13 A15-57 2016-02 St. George’s Respiratory Questionnaire response 22 2 RR
14 A15-45 2016-01 morbidity 24 2 OR
15 A15-31 2015-11 mortality 87 2 RR
16 A15-25 2015-10 serious adverse events 89 2 RR
17 A15-21 2015-07 mortality 16 2 RR
18 S13-04 2015-05 screening for abdominal aortic aneurysm 71 4 OR
19 A15-06 2015-05 morbidity 96 3 RR
20 A15-05 2015-03 morbidity 4 2 RR
21 A14-38 2015-01 serious adverse events 65 3 RR
22 A14-25 2014-11 serious adverse events 115 2 RR
23 A14-22 2014-10 Transition Dyspnea Index responder 67 2 RR
24 A14-19 2014-09 urge to urinate 75 3 RR
25 A14-18 2014-09 persistent virological response (SVR24) 194 3 RR
26 S13-03 2014-06 participants with cervical intraepithelial neoplasia 3+ 15 6 RR
27 A13-29 2013-10 metformidosis 15 3 RR
28 A10-01 2013-08 remissions 1183 2 OR
29 A13-20 2013-08 visual acuity 28 3 RR
30 S11-01 2013-07 bowel cancer 61 7 OR
31 A13-23 2013-06 mortality 15 2 RR
32 A13-05 2013-04 full recovery 19 4 RR
33 A05-10 2013-04 cardiovascular death 75 3 RR
34 A12-19 2013-03 ocular adverse event 17 2 RR
35 A05-18 2012-08 serious adverse events 67 18 OR
36 A12-10 2012-07 adverse events 20 3 RR
37 A12-03 2012-04 loss of transplant 23 2 RR
38 A12-04 2012-04 virus occurrence 22 3 RR
39 A09-05 2012-04 Alzheimer’s Disease Assessment Scale 51 6 OR
40 A11-30 2012-03 mortality 24 2 OR
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Table 2 Abbreviations used for analysis models.
NN-DL Normal-normal (NN) model using the DerSimonian-Laird (DL) heterogeneinty estimator
NN-REML NN model using the restricted maximum-likelihood (REML) estimator
NN-EB NN model using the empirical-Bayes (EB) estimator
PN-PL Poisson model using profile likelihood (PL) estimation
BN-UM.FS Binomial model using unconditional logistic regression and fixed study (nuisance) parameters
BN-UM.RS Binomial model using unconditional logistic regression and random study (nuisance) parameters
BN-CM.EL Conditional (hypergeometric) model (exact likelihood)
BN-CM.AL Conditional (hypergeometric) model (approximate likelihood)
NN-Bayes HN(0.5) NN Bayesian model using a half-normal heterogeneity prior with scale 0.5
NN-Bayes HN(1.0) NN Bayesian model using a half-normal heterogeneity prior with scale 1.0
Table 3 Parameters of the simulation for both effect measures, i.e., relative risk and odds ratio.
Parameter Values
Effect measure (θi) RR, OR
Design equally sized studies,
one small study ( 1
10
size)
one large study (10-fold size)
Observations per study arm (ni) 25, 50, 100, 250, 500, 1000
Number of studies (k) 2, 3, 5, 10
Event rates (p0) 0.1, 0.3, 0.5, 0.7, 0.9
Level of heterogeneity (I2) no heterogeneity: 0.00
low heterogeneity: 0.25
moderate heterogeneity: 0.50
high heterogeneity: 0.75
very high heterogeneity: 0.90
Table 4 Absolute heterogeneity values (τ) corresponding to relative settings (I2) used in the simulations that are shown
in Figures 3 and 4.
relative risk (RR) odds ratio (OR)
I2 equal one small one large equal one small one large
k=2 0.25 0.0534 0.1254 0.0396 0.1781 0.4179 0.1321
0.50 0.0926 0.2171 0.0687 0.3086 0.7237 0.2289
0.75 0.1604 0.3761 0.1189 0.5345 1.2536 0.3964
0.90 0.2777 0.6514 0.2060 0.9258 2.1712 0.6866
k=3 0.25 0.0534 0.1069 0.0447 0.1781 0.3563 0.1491
0.50 0.0926 0.1852 0.0775 0.3086 0.6172 0.2582
0.75 0.1604 0.3207 0.1342 0.5345 1.0690 0.4472
0.90 0.2777 0.5549 0.2324 0.9258 1.8516 0.7746
k=5 0.25 0.0534 0.0844 0.0484 0.1781 0.2981 0.1613
0.50 0.0926 0.1549 0.0838 0.3086 0.5164 0.2795
0.75 0.1604 0.2683 0.1452 0.5345 0.8944 0.4840
0.90 0.2777 0.4648 0.2515 0.9258 1.5491 0.8384
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Table 5 Generation of data sets in the simulation study.
Setting of the parameters
I2, k, ni, P0, case
Determining the vector of study sizes from:
ni and case
Calculation of the variance τ2 = ǫ2 I
2
1−I2
with RR: ǫ2 = 1
k
∑
1
ni
( 2
P0
− 2)
with OR: ǫ2 = 1
k
∑
1
ni
( 2
P0
+ 2
1−P0
)
from I2, ni and k, P0
Generation of the true trial effect size θi from a normal distribution (N(0, τ
2))
Calculation of the true event rates Pa and Pb with:
RR: log(Pa) = log(P0)−
θi
2
log(Pb) = log(P0) +
θi
2
OR: log( Pa
1−Pa
) = log( P0
1−P0
)− θi
2
log( Pb
1−Pb
) = log( P0
1−P0
) + θi
2
Generation of the observed event rates pa (pb) from a Bernoulli distribution with Pa (Pb)
Calculation of the events xit and xic, the θˆi, and σˆ2
i,θˆi
from
pa, pb and ni
repeat with:
rep = 2000
Arranging into one data set
For all combinations
of parameter
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Additional Files
R code for Poisson PL estimation
Shown below is the R code implementing profile likelihood (PL) estimation for the Poisson model according to Bo¨hning et al. [7, Ch. 2]
(see also Methods section).
### Point Estimate under homogeneity
Estimate_PL_Poisson_RR <- function(x.t, n.t, x.c, n.c,
log.effect = TRUE,
s.crit = 0.0000001,
theta.start = 1)
{
w_thetas <- 0
theta_homog <- theta.start
theta_homog_n <- 1
crit <- 1
iter <- 0
while(abs(unlist(crit)) > s.crit) {
w_thetas <- 1/(n.c + theta_homog * n.t) # weight of thetas
# theta under homogeneity:
theta_homog_n <- sum((1/(n.c + w_thetas * n.t)) * x.t * n.c) /
sum((1/(n.c + w_thetas * n.t)) * x.c * n.t)
crit <- theta_homog - theta_homog_n
theta_homog <- theta_homog_n
iter <- iter + 1
}
if (log.effect) {
return(c(log(theta_homog), as.integer(iter)))
} else {
return(c((theta_homog), as.integer(iter)))
}
}
### Variance of the point estimate under homogeneity
Variance_PL_Poisson_RR <- function(x.t, n.t, x.c, n.c,
theta, log.effect=TRUE)
{
if (! log.effect) {
first_term <- sum(x.t)/ (theta^2)
second_term <- - sum(((x.c + x.t) * (n.t^2)) /((n.c + theta * n.t)^2))
return((-(first_term + second_term))^-1)
} else {
theta <- exp(theta)
alpha <- (theta * n.t)/(n.c + theta * n.t)
x_all <- x.t + x.c
return(sum((x_all * alpha * (1-alpha)))^-1)
}
}
### Confidence Interval for the point estimate under homogeneity
CI_PL_Poisson_RR <- function(x.t, n.t, x.c, n.c, theta,
log.effect=TRUE, distr)
{
if (distr == "normal") {
quant <- qnorm(0.975)
}
if (distr == "t-distributed") {
quant <- qt(0.975, length(x.t))
}
if (log.effect) {
variance <- (Variance_PL_Poisson_RR(x.t,n.t,x.c,n.c,theta,log.effect=TRUE)
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+ tau2_theta_Poisson(x.t,n.t,x.c,n.c,theta,log.effect=TRUE))
lower <- theta - quant * sqrt(variance)
upper <- theta + quant * sqrt(variance)
return(c(lower, upper))
} else {
theta <- log(theta)
variance <- (Variance_PL_Poisson_RR(x.t,n.t,x.c,n.c,theta,log.effect=TRUE)
+ tau2_theta_Poisson(x.t,n.t,x.c,n.c,theta,log.effect=TRUE))
lower <- theta - quant * sqrt(variance)
upper <- theta + quant * sqrt(variance)
return(c(exp(lower), exp(upper)))
}
}
### 3. Estimator for the heterogeneity tau^2
mu_poisson <- function(x.t, n.t, x.c, n.c, theta)
{
if (any(x.t == 0) | any(x.t == n.t)) {
x.t <- x.t + 0.5
n.t <- n.t + 0.5
}
if (any(x.c == 0) | any(x.c == n.c)) {
x.c <- x.c + 0.5
n.c <- n.c + 0.5
}
y <- x.t
N <- x.t + x.c
return(sum(y)/sum(N))
}
### Variance of p
tau2_p_Poisson <- function(x.t, n.t, x.c, n.c, theta)
{
y <- x.t
N <- x.t + x.c
p <- (theta*n.t)/(n.c + theta*n.t)
numerator <- (sum((y-N*mu_poisson(x.t, n.t, x.c, n.c, theta))^2)
-(sum(N))*mu_poisson(x.t, n.t, x.c, n.c, theta)
*(1-mu_poisson(x.t, n.t, x.c, n.c, theta)))
denominator <- sum(N*(N-1))
return(numerator/denominator)
}
### Between-study variance
tau2_theta_Poisson <- function(x.t, n.t, x.c, n.c, theta, log.effect=TRUE)
{
if (log.effect) {
result <- (tau2_p_Poisson(x.t, n.t, x.c, n.c, theta)
/ (1-mu_poisson(x.t, n.t, x.c, n.c, theta))^4)
if (any(result < 0)) result[result < 0] <- 0
} else {
result <- (tau2_p_Poisson(x.t, n.t, x.c, n.c, theta)
/ (((mu_poisson(x.t, n.t, x.c, n.c, theta)^2)
*((1 - mu_poisson(x.t, n.t, x.c, n.c, theta))^2))))
if (any(result < 0)) result[result < 0] <- 0
}
return(result)
}
